13
Participants
Start Date
September 11, 2018
Primary Completion Date
November 12, 2018
Study Completion Date
February 12, 2019
Copanlisib (Aliqopa, BAY80-6946)
"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
Metformin
Single dose of 1000 mg is administered orally.
Pharmaceutical Product Development (PPD), LLC, Austin
Lead Sponsor
Bayer
INDUSTRY